Mizuho analyst Graig Suvannavejh expects “material weakness” in Kala Pharmaceuticals shares today after the company announced that KPI-012 failed to achieve all primary and secondary end points in its Phase 2a study in persistent corneal epithelial defect. Kala shares shared no data details and is not hosting a call which is disappointing, the analyst tells investors in a research note. The stock in morning trading is down 90%, or $17.14, to $1.91.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA: